Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Dosing begins in phase II diabetes study of TT-223

Sep. 16, 2008

Recent patent literature covers new antidiabetic agents

Sep. 16, 2008

NicOx's second naproxcinod phase III study meets primary efficacy endpoints

Sep. 16, 2008

MF-101 shows significant improvement in sleep disturbance from hot flashes

Sep. 16, 2008

Recent sanofi-aventis patent reports new antiobesity compounds

Sep. 16, 2008

Drospirenone evaluated as antiadipogenic agent in preclinical studies

Sep. 15, 2008

Oramed signs agreement with ETI Karle Clinical to conduct a phase IIb clinical trial of ORMD-0801

Sep. 12, 2008

Novel treatments for diabetes and related disorders disclosed in recent patents

Sep. 12, 2008

FDA schedules advisory committee meeting with Novo Nordisk for liraglutide NDA

Sep. 12, 2008

Pfizer develops new series of PDE5 inhibitors for once-daily dosing

Sep. 12, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...